GeneBioTech Co. Ltd (086060) - Total Liabilities
Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has total liabilities worth ₩21.41 Billion KRW (≈ $14.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 086060 operating cash flow to assess how effectively this company generates cash.
GeneBioTech Co. Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how GeneBioTech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of GeneBioTech Co. Ltd to evaluate the company's liquid asset resilience ratio.
GeneBioTech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of GeneBioTech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Newtree Co.Ltd
KQ:270870
|
Korea | ₩31.56 Billion |
|
Asiamet Resources Ltd
F:0FK
|
Germany | €850.00K |
|
PT Cilacap Samudera Fishing Industry Tbk
JK:ASHA
|
Indonesia | Rp32.64 Billion |
|
EMMERSON PLC O.N.
F:4UM
|
Germany | €826.00K |
|
Noodles & Company
NASDAQ:NDLS
|
USA | $319.47 Million |
|
Galil Capital Re Spain SOCIMI SA
MC:YGCS
|
Spain | €19.06 Million |
|
Greenyield Bhd
KLSE:0136
|
Malaysia | RM67.64 Million |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
USA | $12.56 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down GeneBioTech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GeneBioTech Co. Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneBioTech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneBioTech Co. Ltd (2009–2024)
The table below shows the annual total liabilities of GeneBioTech Co. Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩21.02 Billion ≈ $14.24 Million |
+18.65% |
| 2023-12-31 | ₩17.71 Billion ≈ $12.00 Million |
-3.29% |
| 2022-12-31 | ₩18.31 Billion ≈ $12.41 Million |
+11.52% |
| 2021-12-31 | ₩16.42 Billion ≈ $11.13 Million |
-3.64% |
| 2020-12-31 | ₩17.04 Billion ≈ $11.55 Million |
-18.86% |
| 2019-12-31 | ₩21.00 Billion ≈ $14.23 Million |
-14.84% |
| 2018-12-31 | ₩24.66 Billion ≈ $16.71 Million |
+29.44% |
| 2017-12-31 | ₩19.05 Billion ≈ $12.91 Million |
-5.37% |
| 2016-12-31 | ₩20.14 Billion ≈ $13.65 Million |
-1.17% |
| 2015-12-31 | ₩20.37 Billion ≈ $13.81 Million |
-14.83% |
| 2014-12-31 | ₩23.92 Billion ≈ $16.21 Million |
-5.26% |
| 2013-12-31 | ₩25.25 Billion ≈ $17.11 Million |
+3.06% |
| 2012-12-31 | ₩24.50 Billion ≈ $16.60 Million |
-8.54% |
| 2011-12-31 | ₩26.79 Billion ≈ $18.15 Million |
+139.51% |
| 2010-12-31 | ₩11.18 Billion ≈ $7.58 Million |
-0.83% |
| 2009-12-31 | ₩11.28 Billion ≈ $7.64 Million |
-- |
About GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.